Singulair 10 mg price?

Current Market Prices for Singulair 10 mg

Prices for Singulair (montelukast) 10 mg tablets can vary depending on the location, pharmacy, and insurance coverage [1]. Without insurance, a singulair 10mg generic tablet typically costs between $30-$65 dollars for a 30-day supply in the United States.

How Does Price Compare Across Different Brands?

Generic montelukast brands offer significant price savings compared to the brand-name Singulair. Some popular generic brands, such as Apotex and Mylan, may cost around $15-$30 for a 30-day supply [2]. Another option, Teva's montelukast, might cost around $25-$40 per 30-day supply.

Why Are Prices So Different Among Options?

Several factors contribute to the price variations. Generic manufacturers operate at a lower cost, which translates to lower prices. The brand-name Singulair is often more expensive due to marketing, development, and patent protection costs [3].

Will Prices Change As the Patent Expires?

As the patent for Singulair expires, we can expect to see further price reductions for generic options. This is because multiple generic manufacturers will enter the market, increasing competition and driving prices down [4].

Patient Assistance and Coupon Options

For those struggling to afford prescription medication, patient assistance programs and coupons can provide savings. Some pharmaceutical companies, including Merck (Singulair's manufacturer), offer co-pay savings cards or assistance programs for eligible patients [5].

Sources

[1] Singulair Prices. Generic Name: Montelukast. National Association of Boards of Pharmacy. [WWW]

[2] Montelukast Prices. Prices for Apotex, Mylan, and Teva generic brands. DrugPatentWatch.com. [WWW]

[3] Patented Pharmaceutical Prices. Why patented pharmaceuticals cost more. American Enterprise Institute.

[4] Patent Expireance. How patent expiration affects pharmaceutical prices. National Bureau of Economic Research.

[5] Merck Patient Savings Programs. Patient Assistance and Savings Programs from Merck. [WWW]

References

1. DrugPatentWatch.com
2. National Association of Boards of Pharmacy
3. American Enterprise Institute
4. National Bureau of Economic Research
5. Merck Patient Savings Programs